Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1)

dc.contributor.author	Koech, D. K
dc.contributor.author	Obel, A. O
dc.contributor.author	Minowada, J
dc.contributor.author	Hutchinson, V. A
dc.contributor.author	Cummins, J. M
dc.date.accessioned	2013-06-11T08:45:27Z
dc.date.available	2013-06-11T08:45:27Z
dc.date.issued	1990
dc.identifier.citation	Mol Biother. 1990 Jun;2(2):91-5.	en
dc.identifier.uri	http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/1973045
dc.identifier.uri	http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/31302
dc.description.abstract	Thirty eight symptomatic and two asymptomatic patients seropositive for human immunodeficiency virus type-1 (HIV-1) were treated with a natural human interferon alpha (HuIFN alpha). Patients were given 2 IU/kg HuIFN alpha orally once daily in powdered maltose held in the mouth to promote mucosal absorption. This oral immunomodulating HuIFN alpha therapy resulted in an increase in CD4+ lymphocytes, an increase in weight, and a dramatic alleviation of clinical symptoms related to HIV-1 infection.	en
dc.language.iso	en	en
dc.title	Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1)	en
dc.type	Article	en